The world dermatological drugs market will reach $24.1BN in 2014, According to A New Report on ASDReports

Monday 2 June 2014, Amsterdam

A new report, now available on ASDReports, predicts that the world market for dermatological drugs will reach $24.1bn in 2014. This forecast and others appear in Dermatological Drugs Market Forecast 2014-2024: Future Prospects for Leading Companies, published in April 2014.

Dermatological drugs are available to treat a range of skin diseases including psoriasis, skin infections, acne and dermatitis/eczema. This specialty area of pharmaceuticals has been growing in recent years due to the availability of blockbuster biological therapies for psoriasis and the launch of new treatments for some infectious skin disorders. Humira, Enbrel and Stelara lead the market in terms of revenue. In other areas mid-size specialist dermatology companies dominate, with Galderma and LEO Pharma ranking in the top ten dermatological drugs companies by revenue.

Thomas Ling, a senior pharmaceutical and medical devices industry analyst and consultant, said: “The dermatological drugs market will grow steadily during 2014-2024. This growth will be driven by the success of biological therapies for psoriasis as well as improved formulations of drugs, such as Cipher’s Absorica (isotretinoin) for severe acne. Antibiotic resistance will provide both challenges and opportunities for developing new antibacterials for the skin infections segment. There is a promising pipeline of new therapies in development. The dermatological drugs market may also see greater interest from big pharma companies looking to take advantage of higher growth in specialist areas such as dermatology. Canada’s Valeant Pharmaceuticals, for example, has been making numerous strategic acquisitions in this area.”

The new report provides revenue forecasts to 2024 for the world dermatological drugs market and leading submarkets. It forecasts sales for the psoriasis, skin infections, acne and dermatitis segments of the market. The report also profiles six leading companies in the ophthalmic drugs market including AbbVie, Galderma, GSK, Johnson & Johnson, LEO Pharma and Pfizer. It also discusses key marketed products, products in the development pipeline, commercial news, and analysis of strengths, weaknesses, opportunities and threats. It includes 4 exclusive interviews with leading industry experts regarding current market trends. The report also includes a Porter’s Five Forces analysis to understand the degree of competitiveness in this market.

Dermatological Drugs Market Forecast 2014-2024: Future Prospects for Leading Companies adds to a range of analytical reports on industries and markets in healthcare.